| Old Articles: <Older 6681-6690 Newer> |
|---|
 |
The Motley Fool
September 13, 2010
Seth Jayson |
What Margins Are Saying at Healthways Here's the current margin snapshot for Healthways and some of its sector and industry peers and direct competitors.   |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
September 10, 2010
Anand Chokkavelu |
How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
September 10, 2010
Seth Jayson |
Will ICON's Next Quarter Be a Bomb? Look here for a clue. |
BusinessWeek
September 9, 2010
Bruce Einhorn |
In Asia, Public Health Care Gets Less Public Health-care policymakers in Asia are encouraging more affluent Asians to use private hospitals and their own funds. |
BusinessWeek
September 9, 2010
Caroline Winter |
A High-End Handler for Deep-Pocketed Patients A startup links the seriously ill with global experts on their malady |
BusinessWeek
September 9, 2010
Michelle Cortez |
Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
The Motley Fool
September 9, 2010
Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
| <Older 6681-6690 Newer> Return to current articles. |
